Tag Archives: Agios Pharmaceuticals

Agios Pharma Soaring 27% Pre-Bell; AG-221 Demonstrates Clinical Acitivity in Blood Cancer Patients

Agios Pharmaceuticals (AGIO) shares were up 27% in recent pre-market trade after saying this weekend that data from a study on the AG-221 drug in patients with advanced blood cancers showed “promising” clinical activity. AGIO is in the upper half of the 52-week range between $15.77 and $49.79. The purpose of the phase 1 program